Unknown

Dataset Information

0

Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.


ABSTRACT: We report a novel phase 2 clinical trial in patients with poor prognosis refractory non-Hodgkin lymphoma (NHL) testing the efficacy of haploidentical donor natural killer (NK) cell therapy (NK dose 0.5-3.27?×?107 NK cells/kg) with rituximab and IL-2 (clinicaltrials.gov NCT01181258). Therapy was tolerated without graft-versus-host disease, cytokine release syndrome, or neurotoxicity. Of 14 evaluable patients, 4 had objective responses (29%; 95% CI 12-55%) at 2 months: 2 had complete response lasting 3 and 9 months. Circulating donor NK cells persisted for at least 7 days after infusion at the level 0.6-16 donor NK cells/µl or 0.35-90% of total CD56 cells. Responding patients had lower levels of circulating host-derived Tregs (17?±?4 vs. 307?±?152 cells/µL; p?=?0.008) and myeloid-derived suppressor cells at baseline (6.6 ± 1.4% vs. 13.0 ± 2.7%; p?=?0.06) than non-responding patients. Lower circulating Tregs correlated with low serum levels of IL-10 (R 2?=?0.64; p?

SUBMITTER: Bachanova V 

PROVIDER: S-EPMC6055922 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells.

Bachanova Veronika V   Sarhan Dhifaf D   DeFor Todd E TE   Cooley Sarah S   Panoskaltsis-Mortari Angela A   Blazar Bruce R BR   Curtsinger Julie M JM   Burns Linda L   Weisdorf Daniel J DJ   Miller Jeffrey S JS  

Cancer immunology, immunotherapy : CII 20171207 3


We report a novel phase 2 clinical trial in patients with poor prognosis refractory non-Hodgkin lymphoma (NHL) testing the efficacy of haploidentical donor natural killer (NK) cell therapy (NK dose 0.5-3.27 × 10<sup>7</sup> NK cells/kg) with rituximab and IL-2 (clinicaltrials.gov NCT01181258). Therapy was tolerated without graft-versus-host disease, cytokine release syndrome, or neurotoxicity. Of 14 evaluable patients, 4 had objective responses (29%; 95% CI 12-55%) at 2 months: 2 had complete re  ...[more]

Similar Datasets

| S-EPMC10859734 | biostudies-literature
2023-01-13 | GSE222369 | GEO
| S-EPMC5817071 | biostudies-literature
| PRJNA920515 | ENA
| S-EPMC4504988 | biostudies-literature
| S-EPMC2582006 | biostudies-literature
| S-EPMC5735063 | biostudies-literature
| S-EPMC9189042 | biostudies-literature
| S-EPMC4335079 | biostudies-literature
| S-EPMC5053680 | biostudies-literature